Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010

• Autores: Kasia J. Lipska, Joseph S. Ross, David Beran
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 311, Nº. 22, 2014, págs. 2331-2333
• Idioma: inglés
• Enlaces
  • Texto Completo Ejemplar
• Resumen

  • Insulin analogs are molecularly altered forms of insulin. Compared with human synthetic and animal insulin for treatment of type 2 diabetes, short-acting analogs may offer flexible dosing and convenience, long-acting analogs less nocturnal hypoglycemia,1 but both at greater cost.2 Because insulin analogs have become increasingly popular,3,4 we examined trends in insulin use, out-of-pocket expenditures, and severe hypoglycemic events among privately insured US adults with type 2 diabetes from 2000 through 2010.